Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
'We recently launched Yesintek in the immunology space.'
'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'
Researchers claim to have developed a new treatment for ovarian cancer that can increase the rate of tumour shrinkage and prolong the time until cancers recur.
Indian firm to soon launch copycat of anti-breast-cancer drug.
